Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amolimogene bepiplasmid - Eisai

Drug Profile

Amolimogene bepiplasmid - Eisai

Alternative Names: E7101; HPV-E6-E7-plasmid; ZYC 101; ZYC00101; ZYC101a

Latest Information Update: 22 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MGI Pharma Biologics
  • Developer Eisai Co Ltd; MGI Pharma Biologics
  • Class Cancer vaccines; DNA; Gene therapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical dysplasia
  • Discontinued Anal dysplasia

Most Recent Events

  • 22 Sep 2017 No recent reports on development identified- Phase-II/III for Cervical dysplasia in USA (IM)
  • 06 Jul 2011 MGI PHARMA completes a phase II/III trial in Cervical dysplasia in US (NCT00264732)
  • 11 Jul 2008 Amolimogene is still in phase II/III trials for Cervical dysplasia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top